Amine Polymer Compositions for Oral Uric Acid Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for gout and hyperuricemia, such as colchicine, are ineffective for many individuals due to severe side effects, and there is a need for new drugs to lower uric acid levels and treat associated diseases.

Innovation Solution

Development of amine polymers, including polyallylamine-based copolymers, that bind to uric acid and its precursors, which can be administered orally to lower serum uric acid levels and treat conditions like gout and hyperuricemia.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If colchicine is administered orally to treat gout, then the treatment effectiveness is improved, but the side effects worsen and cannot be tolerated by 80 percent of people

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses polyallylamine-based copolymers as intermediary substances that bind to uric acid in the gastrointestinal tract, preventing its absorption into the bloodstream. This mediator approach allows uric acid removal without using colchicine's toxic mechanism, thus eliminating severe side effects while maintaining treatment effectiveness for gout and hyperuricemia

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the pharmacological mechanism of colchicine (which affects cellular processes and causes toxicity) with a physical binding mechanism using polymer copolymers. The copolymers physically adsorb uric acid through their molecular structure, substituting the harmful biochemical interaction with a benign physical process that achieves the same therapeutic goal without side effects

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If new drugs are developed to lower uric acid levels, then the treatment options for hyperuricemia and gout are improved, but the need for extensive research and development time increases

Engineering Contradiction:

Improvetreatment optionsVSAvoidresearch and development time

Core Design Contradiction:

Adaptability or versatilityVSLoss of time

Solution Approach 1:

The patent modifies the chemical parameters of polyallylamine by introducing specific copolymer components with uric acid-binding moieties. By changing the polymer's chemical structure and composition parameters, the invention creates effective uric acid-binding copolymers that provide new treatment options for hyperuricemia and gout through a systematic modification approach

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The amine polymers effectively reduce uric acid levels and provide therapeutic benefits for conditions like gout and hyperuricemia, with minimal side effects, and may also protect against kidney damage.

Implementation Method 1

The amine polymer or a salt thereof further comprises a second amine, wherein the second amine is linked to a moiety characterized by selective adsorption of uric acid or precursor thereof

Methodology Applied

Scientific EffectAdsorption: Adsorption

Data Source

PatentUS12478638B2Polymers, compositions and methods for treating hyperuricemia

Publication Date: 2025.11.25 WATERSTONE PHARMA (WUHAN) CO LTD

AI summary

The disclosure provides polymers and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.